MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Wearing-off fluctuations"

  • 2019 International Congress

    Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens

    F. Stocchi, W. Poewe, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

    Objective: Primary analyses of this Phase 2 study have demonstrated significant efficacy of ND0612 in reducing OFF time and improving motor status. This secondary analysis…
  • 2019 International Congress

    Ambulatory monitoring of electrodermal activity (EDA) and Heart Rate Variability (HRV) for prediction of motor fluctuations in Parkinson’s Disease (PD)

    D. Nene, P. Surathi, M. Mirian, W. Doo, M. Mckeown (Vancouver, BC, Canada)

    Objective: To determine whether changes in EDA and HRV are associated with motor fluctuations in patients with PD Background: EDA and HRV are affected in…
  • 2019 International Congress

    A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1

    A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

    Objective: To investigate efficacy and safety of two doses of Opicapone (OPC) compared to placebo administered once daily for 14 to 15 weeks to Japanese…
  • 2019 International Congress

    Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease

    C. Olanow, F. Stocchi, K. Wilks, E. Peckham, M. de Pandis, K. Sciarappa, R. Kleiman, D. Blum, B. Navia (New York, NY, USA)

    Objective: To evaluate efficacy, safety, and tolerability of supratherapeutic doses of apomorphine sublingual film (APL-130277; APL) in patients with Parkinson’s disease (PD) and “OFF” episodes.…
  • 2019 International Congress

    An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2

    A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

    Objective: To investigate the safety and efficacy of continuous treatment with 50 mg Opicapone (OPC) for 1 year after treatment with a placebo, 25 mg…
  • 2019 International Congress

    Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis

    W. Ondo, A. Ellenbogen, S. Isaacson, A. Espay, C. Singer, P. Bhargava, M. Worden, D. Blum, B. Navia (Houston, TX, USA)

    Objective: To examine safety and tolerability of apomorphine sublingual film (APL-130277; APL) during maintenance treatment using pooled data from 4 clinical studies in patients with…
  • 2019 International Congress

    Patient insights into the burden of OFF-episodes in Parkinson’s disease: Qualitative Interviews

    C. Ervin, J. Sutphin, A. Thach, A. Lee, C. Mansfield, J. Coulter (Research Triangle Park, NC, USA)

    Objective: Identify symptoms and impacts associated with OFF-episodes (OEs). Background: OFF-episodes are commonly experienced in patients with Parkinson’s disease (PD).  Qualitative research into patients’ experience…
  • 2019 International Congress

    Diplopia and visual complaints in non-demented patients with Parkinson disease: a Japanese single center cross-sectional survey

    K. Ota, K. Takahashi, K. Seo, H. Kawasaki, K. Ikeda, T. Mitsufuji, T. Fukuoka, Y. Ito, Y. Nakazato, N. Tamura, N. Araki, T. Yamamoto (Saitama-Ken, Japan)

    Objective: To investigate the characterization of diplopia and visual complaints including minor forms of hallucinations (mHals) in non-demented patients with Parkinson disease (PD). Background: Double…
  • 2019 International Congress

    Analysis of Levodopa Content in Commercial Formulations of Mucuna pruriens Seeds Used in Integrative Treatment of Parkinson’s Disease

    T. Denne (Kenmore, WA, USA)

    Objective: Objective: Formulations of Mucuna pruriens (MP) seed products are readily available through the internet and health food stores, and are used by some Parkinson's…
  • 2019 International Congress

    Difference in perception of the wearing-off between patients and physicians in Parkinson’s disease

    Y. Tsuboi, R. Nakagawa, M. Ishido, Y. Yoshinaga, T. Hashimoto, T. Mishima, S. Fujioka (Fukuoka, Japan)

    Objective: To explore if any inconsistency exists in the perception of the presence of wearing-off (WO) symptoms between patients and physicians in Parkinson’s disease (PD).…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 24
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley